Work

Updated efficacy, safety, and exploratory biomarker analyses of a phase II trial of abemaciclib plus hormonal therapy in recurrent ovarian (OC) and endometrial cancer (EC).

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.5516

Authors: Jordyn Silverstein, Chi-Hong Tseng, Ivonne Grande, Lisa Del Rio, Christine Kivork, Evelyn Irene Garcia, James Chauv, Kari Kubalanza, Gottfried E. Konecny

Institutions: University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Ronald Reagan UCLA Medical Center

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Eli Lilly and Company

OpenAlex ID: W7162543395

Cites:

Cited by:

Related to: